Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Senior VP & General Counsel | April 09, 2019 | April 10, 2019 |
| Sunrun Inc.RUN · Entity 4507 | General Counsel | March 15, 2017 | March 17, 2017 |
| Zymergen Inc.ZY · Entity 122955 | Chief Legal Officer | September 02, 2022 | September 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date April 09, 2019 · Filed April 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,389 |
Reported balance
After 2019-04-09 transaction · row 1
1 source rowRow 1 · 2019-04-09 · Tax withholding · Disposed 3,674 · Balance 66,389 F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units.
Sunrun Inc.
Report date March 15, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 327,606 |
Reported balance
After 2017-03-15 transaction · row 1
1 source rowRow 1 · 2017-03-15 · Grant · Acquired 131,000 · Balance 327,606 F1: Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs will vest on March 15, 2018, and the remaining RSUs will vest quarterly over the following three years, subject to the Reporting Person's continued service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2027-03-14 | Direct | 316,000 |
Reported balance
After 2017-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-15 · Grant · Acquired 316,000 · Balance 316,000 F2: 25% of the shares subject to the option will vest on March 15, 2018, and 1/48 of the shares will vest monthly thereafter, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs will vest on March 15, 2018, and the remaining RSUs will vest quarterly over the following three years, subject to the Reporting Person's continued service through each vesting date.
F2: 25% of the shares subject to the option will vest on March 15, 2018, and 1/48 of the shares will vest monthly thereafter, subject to the Reporting Person's continued service through each vesting date.
Zymergen Inc.
Report date September 02, 2022 · Filed September 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 298,427 |
Reported balance
After 2022-09-02 transaction · row 1
1 source rowRow 1 · 2022-09-02 · Sale · Disposed 3,410 · Balance 298,427 F1: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.31 and no less than $2.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.31 and no less than $2.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-21 · Grant · Acquired 89,526 · Balance 770,833 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. F3: (Continued from Footnote 2) At the Effective Time, each outstanding performance-based restricted stock unit ("PSU") award that was outstanding and unvested immediately prior to the Effective Time was deemed earned at 100% of the target level of performance and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the target number of shares subject to the PSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. Row 2 · 2025-05-21 · Disposition to issuer · Disposed 770,833 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. F3: (Continued from Footnote 2) At the Effective Time, each outstanding performance-based restricted stock unit ("PSU") award that was outstanding and unvested immediately prior to the Effective Time was deemed earned at 100% of the target level of performance and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the target number of shares subject to the PSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2034-05-25 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 1,195,856 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/4 of the shares subject to the option vested on May 9, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68 · Expires 2034-01-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 190,114 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F6: 1/4 of the shares subject to the option vested on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 85,226 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F7: 1/4 of the shares subject to the option vested on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 362,719 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F8: 1/4 of the shares subject to the option vested on November 14, 2023, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share.
F3: (Continued from Footnote 2) At the Effective Time, each outstanding performance-based restricted stock unit ("PSU") award that was outstanding and unvested immediately prior to the Effective Time was deemed earned at 100% of the target level of performance and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the target number of shares subject to the PSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share.
F4: 1/4 of the shares subject to the option vested on May 9, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F5: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F6: 1/4 of the shares subject to the option vested on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F7: 1/4 of the shares subject to the option vested on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F8: 1/4 of the shares subject to the option vested on November 14, 2023, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 362,719 | Not disclosed Strike: $5.88 | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · derivative · entry 6 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 362,719 shares Expires 2032-11-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on November 14, 2023, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 85,226 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · derivative · entry 5 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,226 shares Expires 2033-05-03 F5 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 190,114 | Not disclosed Strike: $7.68 | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · derivative · entry 4 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,114 shares Expires 2034-01-08 F5 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,195,856 | Not disclosed Strike: $4.13 | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · derivative · entry 3 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,195,856 shares Expires 2034-05-25 F5 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 9, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerCommon Stock | 770,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · nonDerivative · entry 2 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2 · price: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. F3 · price: (Continued from Footnote 2) At the Effective Time, each outstanding performance-based restricted stock unit ("PSU") award that was outstanding and unvested immediately prior to the Effective Time was deemed earned at 100% of the target level of performance and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the target number of shares subject to the PSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 89,526 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001962918-25-000068 · wk-form4_1748031106.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770,833 F1 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2 · price: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. F3 · price: (Continued from Footnote 2) At the Effective Time, each outstanding performance-based restricted stock unit ("PSU") award that was outstanding and unvested immediately prior to the Effective Time was deemed earned at 100% of the target level of performance and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the target number of shares subject to the PSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:46 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Tax withholdingCommon Stock | 10,258 | $2.17 | $22,259.86 |
DisclosureSEC source: 0001962918-25-000038 · wk-form4_1747687568.xml · nonDerivative · entry 3 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 681,307 F3 · shares: Represents the total number of shares withheld to settle the Reporting Person's tax liability for restricted stock units that vested on May 15, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:46 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Tax withholdingCommon Stock | 11,039 | $2.17 | $23,954.63 |
DisclosureSEC source: 0001962918-25-000038 · wk-form4_1747687568.xml · nonDerivative · entry 2 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,565 F2 · shares: Represents the total number of shares withheld to settle the Reporting Person's tax liability for the PSUs that vested on May 15, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:46 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 30,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-25-000038 · wk-form4_1747687568.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,604 F1 · shares: On May 15, 2025, the Reporting Person vested in a portion of a previously granted performance-based restricted stock unit ("PSU") award pursuant to the terms of the Company's 2023 Equity Incentive Plan and the applicable PSU Award Agreement. The Compensation Committee certified that the Company achieved 64% of the performance goals related to Tranche 1 of 3, based on the volume-weighted average trading price over the 20-day period ending April 1, 2025. The remaining unvested PSUs from Tranche 1 were forfeited. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 18:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | SaleCommon Stock | 17,986 | $2.74 | $49,353.58 |
DisclosureSEC source: 0001962918-25-000031 · wk-form4_1742422260.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671,753 F1 · kind: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.76 and no less than $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:02 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 575,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-25-000007 · wk-form4_1737759727.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,739 F1 · shares: Represents Restricted Stock Units (RSUs) that vest in twelve (12) equal quarterly installments over three (3) years, beginning on March 15, 2025, and continuing on June 15, September 15, and December 15, 2025, and on the same dates in each subsequent year, subject to the Reporting Person's continued service through each vesting date. F2 · balance_after: Includes 4,000 shares of Common Stock acquired pursuant to the Issuer's 2023 Employee Stock Purchase Plan (ESPP) for the purchase period from June 15, 2024, to December 14, 2024. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on December 13, 2024, the last trading day immediately preceding the purchase period end date. Read SEC document |
| May 26, 2024 Filed May 28, 2024 19:03 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 1,195,856 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001962918-24-000077 · wk-form4_1716937402.xml · derivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,195,856 Underlying: Common Stock · 1,195,856 shares Expires 2034-05-25 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 9, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 15, 2024 Filed May 17, 2024 19:09 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Tax withholdingCommon Stock | 10,230 | $4.47 | $45,728.10 |
DisclosureSEC source: 0001962918-24-000061 · wk-form4_1715987382.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,739 F1 · shares: Represents the total number of shares withheld to settle the Reporting Person's tax liability for the Restricted Stock Units that vested on May 15, 2024. F2 · balance_after: Includes 1,293 shares of Common Stock acquired pursuant to the Issuer's 2023 Employee Stock Purchase Plan ("ESPP"), for the purchase period of June 15, 2023 to December 14, 2023. This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on December 14, 2023. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 18:34 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 190,114 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001962918-24-000008 · wk-form4_1705016077.xml · derivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,114 Underlying: Common Stock · 190,114 shares Expires 2034-01-08 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:52 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 114,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000023 · wk-form4_1692399144.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,676 F1 · shares: Represents Restricted Stock Units (RSUs). 1/4 of the RSUs will vest on May 15, 2024 and the remaining RSUs will vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 85,226 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028870 · doc4.xml · derivative · entry 5 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,226 Underlying: Common Stock · 85,226 shares Expires 2033-05-03 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 85,226 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028870 · doc4.xml · derivative · entry 4 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 85,226 shares Expires 2033-05-03 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 362,719 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001209191-23-028870 · doc4.xml · derivative · entry 3 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,719 Underlying: Common Stock · 362,719 shares Expires 2032-11-20 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 14, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 362,719 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001209191-23-028870 · doc4.xml · derivative · entry 2 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 362,719 shares Expires 2032-11-20 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 14, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | PurchaseCommon Stock | 5,000 | $18.00 | $90,000.00 |
DisclosureSEC source: 0001209191-23-028870 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). Read SEC document |
| May 04, 2023 Filed May 4, 2023 20:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 85,226 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027520 · doc4.xml · derivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,226 Underlying: Class A Common Stock · 85,226 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 19:31 UTC | Zymergen Inc. ZY · Entity 122955 | SaleCommon Stock | 3,410 | $2.21 | $7,536.10 |
DisclosureSEC source: 0001645842-22-000124 · wf-form4_166259346829299.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,427 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.31 and no less than $2.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 17:36 UTC | Zymergen Inc. ZY · Entity 122955 | SaleCommon Stock | 3,094 | $2.61 | $8,083.08 |
DisclosureSEC source: 0001645842-22-000107 · wf-form4_165964892763630.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,837 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.69 and no less than $2.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 16:54 UTC | Zymergen Inc. ZY · Entity 122955 | SaleCommon Stock | 2,924 | $1.32 | $3,866.41 |
DisclosureSEC source: 0001645842-22-000102 · wf-form4_165722724989335.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,931 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $1.36 and no less than $1.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 19:30 UTC | Zymergen Inc. ZY · Entity 122955 | SaleCommon Stock | 2,939 | $1.68 | $4,930.47 |
DisclosureSEC source: 0001645842-22-000100 · wf-form4_165455821812926.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,855 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $1.70 and no less than $1.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 02, 2022 Filed May 4, 2022 18:17 UTC | Zymergen Inc. ZY · Entity 122955 | SaleCommon Stock | 3,206 | $1.79 | $5,739.70 |
DisclosureSEC source: 0001645842-22-000061 · wf-form4_165170260072260.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,794 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $1.84 and no less than $1.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 18:41 UTC | Zymergen Inc. ZY · Entity 122955 | GrantCommon Stock | 217,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001645842-22-000030 · wf-form4_164738409104866.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,000 F1 · shares: Represents Restricted Stock Units (RSUs) that vest 1/24 on each monthly anniversary of the first day of the calendar month immediately following the Grant Date, March 11, 2022, subject to the grantee's continuous service through each such vesting date. F2 · balance_after: Includes 97,000 Restricted Stock Units (RSUs) that vest 1/3 on November 1, 2022 and the remaining 2/3 on November 1, 2023, subject to the Reporting Person's continued service to the Company through thevesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 20:18 UTC | Zymergen Inc. ZY · Entity 122955 | GrantStock Options · Derivative | 194,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-21-131243 · tm2131339d1_4.xml · derivative · entry 2 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires 2031-10-26 F2 · derivative.exercise_date: The shares subject to the Option vest in 48 equal installments on each monthly anniversary of October 25, 2021, in each case subject to the Reporting Person's continued service to the Company through the applicable vesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 20:18 UTC | Zymergen Inc. ZY · Entity 122955 | GrantCommon Stock | 97,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-131243 · tm2131339d1_4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 F1 · shares: Represents Restricted Stock Units (RSUs) that vest 1/3 on November 1, 2022 and the remaining 2/3 on November 1, 2023, subject to the Reporting Person's continued service to the Company through the vesting date. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 16:33 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 3,674 | $36.85 | $135,386.90 |
DisclosureSEC source: 0001209191-19-024245 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,389 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 17:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021444 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,063 F1 · shares: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,125 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008514 · doc4.xml · derivative · entry 2 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,125 Underlying: Common Stock · 34,125 shares Expires 2029-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service.. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 17,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008514 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,063 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. F2 · balance_after: Includes 500 shares purchased on November 30, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 20:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $36.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024449 · doc4.xml · derivative · entry 2 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2025-04-08 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on April 9, 2019 and the remaining shares vest in equal monthly installments over the following 36 months. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 20:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024449 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 F1 · shares: 25% of the shares subject to restricted stock units vest on April 9, 2019 and the remaining shares vest in equal annual installments over the following 3 years. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:28 UTC | Sunrun Inc. RUN · Entity 4507 | GrantEmployee Stock Option (right to buy) · Derivative | 316,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-021494 · doc4.xml · derivative · entry 2 Kim Mina · CIK 0001668163 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,000 Underlying: Common Stock · 316,000 shares Expires 2027-03-14 F2 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 15, 2018, and 1/48 of the shares will vest monthly thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:28 UTC | Sunrun Inc. RUN · Entity 4507 | GrantCommon Stock | 131,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-021494 · doc4.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,606 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs will vest on March 15, 2018, and the remaining RSUs will vest quarterly over the following three years, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 21:07 UTC | Sunrun Inc. RUN · Entity 4507 | GrantCommon Stock | 87,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-16-007128 · form.xml · nonDerivative · entry 1 Kim Mina · CIK 0001668163 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,606 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). 1/24 of the RSUs will vest on January 1, 2017, and 1/24 of the RSUs will vest monthly thereafter, subject to the Reporting Person continuing in active service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.